- COMBINED THERAPEUTIC EFFICACY

Dapagliflozin

Insulin independent action – Glycosuria


  • Cardio renal benefits
  • Weight reduction

Glimepiride

Increases insulin Secretion


  • Potent modern SU
  • Cardio Renal Safe

Metformin

Decreases insulin Sensitivity


  • Potential CV benefit
  • Weight reduction

DAPATURN EFFICACY HIGHLIGHTS

Early initiation reduces cardio renal-metabolic risks

Decline in composite cardio*-renal outcomes by 39%

Dapagliflozin improves GV and TIR by 26.5%

4 Decreases HbA1c and reduces hepatic and pancreatic fat

FPG and PPG reduction of -28.1 mg/dl and -54.3 mg/dl respectively

Low risk of GTI

39% RRR in sustained decline in the eGFR of at least 50%, ESKD, or death from renal or CV causes

COMPREHENSIVE APPROACH TO THE OMINOUS OCTET

Other SKU